KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Invested Capital: 2009-2025

Historic Invested Capital for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $917.3 million.

  • Acadia Pharmaceuticals' Invested Capital rose 58.92% to $917.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $917.3 million, marking a year-over-year increase of 58.92%. This contributed to the annual value of $732.8 million for FY2024, which is 69.72% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Invested Capital is $917.3 million, which was up 11.54% from $822.4 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Invested Capital's 5-year high stood at $917.3 million during Q3 2025, with a 5-year trough of $362.2 million in Q3 2023.
  • Over the past 3 years, Acadia Pharmaceuticals' median Invested Capital value was $516.7 million (recorded in 2024), while the average stood at $578.1 million.
  • In the last 5 years, Acadia Pharmaceuticals' Invested Capital fell by 25.97% in 2022 and then soared by 69.72% in 2024.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Invested Capital stood at $540.9 million in 2021, then fell by 25.97% to $400.4 million in 2022, then climbed by 7.83% to $431.8 million in 2023, then skyrocketed by 69.72% to $732.8 million in 2024, then surged by 58.92% to $917.3 million in 2025.
  • Its Invested Capital was $917.3 million in Q3 2025, compared to $822.4 million in Q2 2025 and $765.2 million in Q1 2025.